Dr. Sherief H. Gamie reviews how multiparametric MRI, PSMA PET, and micro-ultrasound are transforming prostate cancer diagnosis by improving patient selection for biopsy, reducing unnecessary invasive procedures, and supporting a more individualized, imaging-guided diagnostic pathway.
Read More
Dr. E. David Crawford reviews the evolution of PSA screening, lessons from major clinical trials, and the development of a practical, risk-adapted approach that combines PSA, biomarkers, MRI, and clinical risk assessment to improve early detection of prostate cancer while reducing unnecessary biopsies and overtreatment.
Read More
Sean P. Collins reviews how PSA screening has evolved toward individualized, risk-adapted care, highlighting the roles of serial PSA testing, MRI, and secondary biomarkers while discussing practical strategies to improve prostate cancer detection and reduce unnecessary biopsies.
Read More
Helen L. Bernie, DO, MPH, reviews evidence on testosterone therapy and prostate cancer risk and management.
Read More
Institutional experience supports focal therapy as an option for selected men with focal prostate cancer.
Read More